Taiwan’s Food and Drug Administration (TFDA) has recalled of 87,360 tablets of a blood pressure medication after a specific batch failed a quality test. Health officials raised concerns, saying that the drug may not work as effectively as expected. The recall involves Beniel F.C. Tablets 8 mg, manufactured by Synmosa Biopharma Corp. The affected batch is 2KA31, and the medicine contains benidipine hydrochloride, a drug used to treat high blood pressure. Why Has The Blood Pressure Medicine Been Recalled? The problem was first identified during a stability test of the drug, which found that the tablets failed to meet the required dissolution standards. In simple terms, a dissolution test is conducted to check how a tablet breaks down and releases its active ingredient under controlled conditions. This is an important test as a tablet has to release the medicine in the proper way for the body to absorb it and for the drug to produce its intended effect. TFDA official Liu Chia-ping said the failed test could affect the medicine’s quality and overall effectiveness. The recall was initiated after the manufacturer notified the regulator about the problem. This does not mean that all Beniel F.C. Tablets are defective. The regulator said that the recall is limited to batch 2KA31.Also read: Blood Pressure, Heart Medicines May Boost Effectiveness Of Antidepressants, AIIMS Study Finds What Is Benidipine And How Does It Work? Benidipine hydrochloride belongs to a group of drugs called calcium channel blockers. These medicines help lower blood pressure by relaxing and widening blood vessels. This enables the blood to flow more easily and reduces the pressure against artery walls. That is why a problem affecting how a tablet dissolves can matter. If the active ingredient is not released into the body as expected, the medicine may not deliver its intended therapeutic effect.Also read: Why Are More Women Under 35 Reporting Heart-Related Symptoms? Is There A Risk Of Medicine Shortage? According to the TFDA, there is no immediate concern of medication shortage. Other batches of Beniel F.C. Tablets 8 mg are not affected, and the manufacturer has sufficient inventory. Production of the drug will also not been stopped. Taiwan News reported that two other products containing the same active ingredient are also authorised for sale. The manufacturer has been ordered to complete the recall by August 24 and submit an investigation report along with corrective and preventive measures for future production.Also read: Smoking, Diabetes, High Blood Pressure May Fuel the Most Dangerous Type of Artery Plaque, Study FindsWhat Should Patients Taking Medicine From Recalled Batch Do? Patients should not stop their blood pressure medication on their own. The TFDA advised people who are concerned about their prescription to speak with their doctor about whether an alternative medicine is necessary. The recall highlights an often overlooked part of medication safety: a medicine can contain the correct active ingredient but still fail a quality test if its physical properties affect how the drug is released. For now, the concern is focused on one specific batch, rather than the entire Beniel F.C. product line.